Stratification of patients by treatment with nivolumab revealed a strikingly high odds ratio of EGFR–TKI-associated ILD (5.09, 95% CI 2.87–9.03) compared to those who did not receive nivolumab 1.22 (95% CI 1.00–1.47); however, authors did not specify which EGFR-TKI was used in those who developed ILD. The gene discussed is EGFR; the disease is interstitial lung disease.